{"prompt": "['Product: MK-3475', '18', 'Protocol/Amendment No.: 604-09', 'the Second Course Phase. Response or progression during the Second Course Phase will not', 'be included in the analyses of the ORR or PFS endpoints in this trial.', 'After the end of treatment, each subject will be followed for a minimum of 30 days for AE', 'monitoring even if the subject started non-study antineoplastic treatment. Serious adverse', \"events (SAEs) will be documented for up to 90 days following cessation of the Sponsor's\", 'product, or 30 days following cessation of treatment if the subject initiates non-study cancer', 'treatment, whichever is earlier. After this period, any SAEs considered to be related to the', 'trial treatment must be reported. Subjects will have post-treatment follow-up for disease', 'status, until initiating a non-study cancer treatment, experiencing disease progression or', 'death, withdrawing consent, or becoming lost to follow-up. After documented disease', 'progression or the start of non-study cancer treatment, subjects will have contact with study', 'personnel by telephone until death, withdrawing consent, or becoming lost to follow-up. The', 'Sponsor may request survival status to be assessed at additional time points and entered into', 'the database during the course of the trial. For example, survival status may be requested', 'prior to, but not limited to, external Data Monitoring Committee (DMC) reviews, as well as', 'at interim and/or final analyses.', 'This trial has dual primary endpoints: 1) PFS as assessed by BICR per RECIST 1.1 modified', 'to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ and 2)', 'overall survival (OS). Trial results will be considered positive if the hypothesis test for either', 'one of these primary endpoints is successful. Efficacy also will be evaluated using ORR (key', 'secondary endpoint) and duration of response (duration of response [DOR]; secondary', 'endpoint) as assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target', 'lesions and a maximum of 5 target lesions per organ (Details are provided in the Site Imaging', 'Manual).', 'Safety will be assessed using NCI CTCAE 4.0 and is a secondary endpoint. Quality of life', 'assessments encompass both secondary and exploratory endpoints. Additional exploratory', 'analyses will include: PFS using investigator-assessed irRECIST; ORR using investigator-', 'assessed irRECIST; DOR using investigator-assessed irRECIST; PFS, OS, and ORR in', 'PD-L1 subgroups; and identification of additional biomarkers of response.', 'Two interim efficacy analyses and 1 final analysis are planned in this study. This trial will', 'use a group sequential design based on pre-specified criteria, using an independent, external', 'DMC to monitor safety and efficacy results. Details are described in Section 8.0.', 'Specific procedures to be performed during the trial, as well as their prescribed times and', 'associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each', 'procedure are provided in Section 7.0 - Trial Procedures.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '19', 'Protocol/Amendment No.: 604-09', '2.2 Trial Diagram', 'Inclusion:', 'No untreated or unstable brain', 'Untreated, newly diagnosed,', 'metastases', 'extensive stage SCLC', 'No autoimmune diseases,', 'Measurable disease (RECIST 1.1)', 'paraneoplastic syndromes, or', 'ECOG 0-1', 'interstitial lung disease', 'Prophylactic Cranial', 'Irradiation', 'Arm 1: Pembrolizumab+EP', \"(Investigator's discretion)\", 'N 215', 'Pembrolizumab', 'Pembrolizumab 200 mg', '200 mg', 'PD', 'Q3W x additional', 'Etoposide/Platinum', '31 cycles', 'Q3W x4 cycles', '1:1 Randomization', 'N 430', 'Stratification factors:', 'Follow-up', 'Cisplatin or carboplatin', 'ECOG status (0 or 1)', 'LDH (= or > ULN)', 'Arm 2: Placebo+EP', 'N=215', 'Placebo', 'Placebo', 'PD', 'Q3W x additional', 'Etoposide/Platinum', '31 cycles', 'Q3W x 4 cycles', 'Prophylactic Cranial', 'Irradiation', \"(Investigator's discretion)\", 'Abbreviations: ECOG=Eastern Cooperative Oncology Group, EP=etoposide / platinum, LDH=lactate dehydrogenase,', 'PD=progressive disease, PFS=progression-free survival, Q3W=every 3 weeks, RECIST 1.1=Response Evaluation Criteria', 'in Solid Tumors version 1.1, SCLC=small cell lung cancer, ULN=upper limit of normal', 'See Study Flow Chart (Section 6.2) for details regarding Second Course Phase', 'Figure 1', 'Trial Design Overview', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}